CTOs on the Move

Aeras Global TB Vaccine Foundation

www.aeras.org

 
Aeras is constantly producing new constructs that will also be made available following phenotypic, genotypic and stability characterization. Aeras is also glad to provide shigella carrier strains with capsids expressing TB antigens under similar
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.aeras.org
  • 1405 Research Blvd
    Rockville, MD USA 20850
  • Phone: 301.547.2900

Executives

Name Title Contact Details

Similar Companies

Medical Technology Systems

Medical Technology Systems, Inc. is a Saint Petersburg, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Smiles Dental

Welcome to Smiles Dental! Were proud to offer One of a Kind(ness) dentistry at our convenient offices across Washington and Oregon.

Carrollwood Pharmacy

Carrollwood Pharmacy is a Tampa, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Syneos Health

"Syneos Health® (Nasdaq:SYNH) is a leading fully integrated biopharmaceutical solutions organization built to accelerate customer success. We translate unique clinical, medical affairs and commercial insights into outcomes to address modern market realities. We bring together a talented team of professionals, who work across more than 110 countries, with a deep understanding of patient and physician behaviors and market dynamics. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers` delivery of important therapies to patients. Syneos Health supports a diverse, equitable and inclusive culture that cares for colleagues, customers, patients, communities and the environment. "

Edgewise Therapeutics

Edgewise Therapeutics is a biotechnology company harnessing proven expertise and understanding of skeletal muscle physiology to develop novel, transformative therapies for serious muscle diseases. Based in Boulder, Colorado, we have built a state-of-the-art muscle research facility to capitalize on new insights into the nature and consequences of muscle adaptation and injury with disease. Edgewise recently closed it`s Series B financing round which will support the advancement of Edgewise Therapeutic`s lead product candidate into clinical development for Duchenne and Becker Muscular Dystrophy (DMD and BMD) as well as expansion of the company`s pipeline. The company`s leadership team has founded multiple biotechnology startups, several of which have gone on to become publicly-traded companies and brings to bear a depth of experience in drug discovery, development and commercialization.